Striking study results last year indicated a new type of medicine may improve on Merck’s immunotherapy, spurring a wave of ...

PD-1 blockade conferred benefit to certain women with surgically resectable endometrial cancer, findings presented at Society ...

An early pilot trial suggests that combining atezolizumab (tecectriq) with rituximab (Rituxan), gemcitabine (gemzar) and ...

programmed cell death protein 1 (PD-1) has been regarded as a leading target in cancer treatments. A checkpoint receptor that often resides on the surface of immune system cells, the PD-1 molecule ...

A 3-D image shows a T cell expressing the immune checkpoint receptor PD-1 (green) interacting with an antigen presenting cell expressing the ligand PD-L1 (magenta).

and Palobiofarma’s adenosine A2A receptor inhibitor taminadenant (NIR178) in various cancer indications. With six PD-1/PD-L1 inhibitors on the market – and the most recent entrants struggling ...

The table is a review of notable updates that occurred in February 2025 for investigational products in development.

PD-L1 is a cell surface receptor expressed on both tumour and regulatory ... given as a monotherapy or in combination with MSD’s PD-1 inhibitor Keytruda (pembrolizumab), a widely-used treatment ...

DelveInsight's "BAVENCIO Market Size, Forecast, and Market Insight Report" highlights the details around BAVENCIO, a human ...

Tharimmune (THAR) announced the expansion of its product pipeline with HS1940, a dual-target multispecific biologic engineered to bind to both ...